By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Horizon Discovery today announced it has completed its acquisition of contract research organization Hypoxium and formed a wholly owned subsidiary called Horizon Discovery Services.

HDS will provide oncology translational research services, such as drug profiling, novel 2D and 3D phenotypic assays, tumor microenvironment studies, and responsive-patient prediction. The services include access to Horizon's 250-plus patient relevant human isogenic cancer cell models.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.